BRCA1 and pancreatic neoplasm: In a retrospective analysis of 24,849 patients with breast, ovarian, prostate and pancreatic cancers with DDR mutations (BRCA1/2, ATM, PALB2, CHEK2) Marshall et al. found that 14% patients had CH [67, 68].